|
|
 |
|
Viewing report
|
|
|
|
Pfizer: Pipeline, Products, Performance, Potential
Espicom Business Intelligence Ltd, Nov 2010, Pages: 228
Headquartered in New York, Pfizer has been the world's largest research-based pharmaceutical company since it stole Merck & Co's crown in 1998. The subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000 and the merger with Pharmacia in April 2003 (which included the former Monsanto division, GD Searle) cemented this position. Furthermore, in October 2009, the company acquired Wyeth, another leading global pharmaceutical company, in a deal valued at around US$68 billion, which should help the company maintain a leadership position in the longer-term.
Pfizer has a broad portfolio, with strengths in the areas of cardiovascular disease, central nervous system disorders, inflammatory disease, metabolic disorders, infectious diseases and oncology.
Employing over 116,500 people worldwide, it has more than 100 overseas subsidiaries and operations in around 150 countries.
Pfizer believes it has one of the broadest product portfolios of all the major pharmaceutical companies. In 2004, Pfizer set an industry record with ten of its products (including Celebrex) generating revenues of more than US$1 billion each; in 2009 this number was reduced to nine.
|
|
|
|
